pfizer oral glp-1 Discontinues Development of Investigational for Weight Management naperiglipron (LY3549492)

Each product is developed with carefully selected ingredients to ensure quality and performance

Beaver, L

With expert guidance and targeted supplements, youll have the tools to maintain your energy and stay on track toward your goals

They result from slowed gastric emptying allowing bacterial fermentation in the stomach, and the change in gastric motility patterns during medication transitions can exacerbate them temporarily

LLY also announced in mid-February 2024 that a phase 2 trial evaluating tirzepatide for liver disease metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), met its primary endpoint where up to 74% of participants achieved resolution of MASH with no worsening of fibrosis, compared to 13% on placebo